J&J loses patent suit over dementia med

Seven generics makers are high-fiving today after a federal judge declared Johnson & Johnson's patent on Alzheimer's med Razadyne invalid. The ruling is the latest development in a long-standing dispute over the patent that started when J&J sued the copycats to keep their versions off the market. Now, J&J says it will appeal the judge's decision, but Barr, for one, says it's going to launch its generics straight away. So does Mylan.

The other generics makers involved are Teva--which is buying Barr--plus Dr. Reddy's Laboratories, Par Pharmaceuticals, and units of Actavis and Merck KGaA. Razadyne accounted for $214 million of J&J's 2007 sales.

- read J&J's Ortho-McNeil release
- check out the story in the Star-Ledger
- see the Interactive Investor news
- get the Wall Street Journal article

 

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.